LUCD - Lucid Diagnostics Inc.

QQQ $ 476.00 $ 5.61 (1.19 %)

DIA $ 416.44 $ 2.30 (0.56 %)

SPY $ 563.62 $ 5.33 (0.95 %)

TLT $ 96.60 $ -1.04 (-1.07 %)

GLD $ 231.30 $ -1.66 (-0.71 %)

Previous Close

$ 0.8004

Open

$ 0.79

Bid

$ 0.79 x 162

Ask

-- x --

Day's Range

$ 0.78 - $ 0.80

52 Week Range

$ 0.63 - $ 1.72

Volume

60,670

Average Volume

Market Cap

43.21M

Beta (5Y Monthly)

$ 1.23

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	08-12-2024	06-30-2024	10-Q
2	05-13-2024	03-31-2024	10-Q
3	03-25-2024	12-31-2023	10-K
4	11-13-2023	09-30-2023	10-Q
5	08-14-2023	06-30-2023	10-Q
6	05-15-2023	03-31-2023	10-Q
7	03-14-2023	12-31-2022	10-K
8	11-14-2022	09-30-2022	10-Q
9	08-15-2022	06-30-2022	10-Q
10	05-16-2022	03-31-2022	10-Q
11	04-06-2022	12-31-2021	10-K
12	11-23-2021	09-30-2021	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Lucid Diagnostics Announces Publication Of...
08/20/2024 12:18:07

Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical d...

Canaccord Genuity Maintains Buy on Lucid D...
08/13/2024 16:24:15

Canaccord Genuity analyst Kyle Mikson maintains Lucid Diagnostics (NASDAQ:LUCD) with a Buy and maintains $3 price target.

Lucid Diagnostics Announced That The Ameri...
08/13/2024 12:55:19

Request for insurance coverage aims to enhance early detection and treatment of esophageal precancer to prevent highly lethal e...

Needham Reiterates Buy on Lucid Diagnostic...
08/13/2024 10:05:17

Needham analyst Mike Matson reiterates Lucid Diagnostics (NASDAQ:LUCD) with a Buy and maintains $2.5 price target.

Lucid Diagnostics Q2 2024 Adj EPS $(0.20) ...
08/12/2024 12:08:57

Lucid Diagnostics (NASDAQ:LUCD) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0...

Lucid Diagnostics Announces New Real-World...
08/06/2024 12:17:13

Lucid Diagnostics Reports 31% Increase In ...
07/23/2024 12:04:49

Lucid Diagnostics shares are trading highe...
07/02/2024 12:06:35

Lucid Diagnostics Announces Data From ESOG...
07/02/2024 11:56:22

Lucid Diagnostic Reports 4,000 Firefighter...
06/12/2024 12:11:26

Firefighter #CheckYourFoodTube Precancer Testing Event organized by Mass General Brigham physicians and Boston Firefighters Loc...

Ascendiant Capital Maintains Buy on Lucid ...
06/06/2024 17:14:08

Ascendiant Capital analyst Edward Woo maintains Lucid Diagnostics (NASDAQ:LUCD) with a Buy and lowers the price target from ...

Cantor Fitzgerald Reiterates Overweight on...
05/15/2024 12:25:31

Cantor Fitzgerald analyst Ross Osborn reiterates Lucid Diagnostics (NASDAQ:LUCD) with a Overweight and maintains $3 price ta...

Needham Reiterates Buy on Lucid Diagnostic...
05/13/2024 15:50:49

Needham analyst Mike Matson reiterates Lucid Diagnostics (NASDAQ:LUCD) with a Buy and maintains $2.5 price target.

Lucid's Chairman And CEO Says We Strengthe...
05/13/2024 12:08:47

Lucid Diagnostics Q1 2024 Adj EPS $(0.21) ...
05/13/2024 12:03:45

Lucid Diagnostics (NASDAQ:LUCD) reported quarterly losses of $(0.21) per share which beat the analyst consensus estimate of $(0...

Lucid Diagnostics Says EsophaCap Device Re...
05/09/2024 12:23:10

Lucid Diagnostics Announces Peer-Reviewed ...
05/02/2024 11:54:18

EsoGuard demonstrated unprecedented early precancer detection, including 89% sensitivity at detecting short segment early preca...

12-health-care-stocks-moving-in-tuesdays-intraday-session

12 Health Care Stocks Moving In Tuesday's ...
04/30/2024 16:31:18

12-health-care-stocks-moving-in-mondays-after-market-session

12 Health Care Stocks Moving In Monday's A...
04/29/2024 20:31:14

Needham Reiterates Buy on Lucid Diagnostic...
04/12/2024 08:37:23

Needham analyst Mike Matson reiterates Lucid Diagnostics (NASDAQ:LUCD) with a Buy and maintains $2.5 price target.